 |
 |
Schwarz Pharma to file for worldwide approval of Parkinson's patch in Q3, 2004. MONHEIM, Germany, Oct 27, 2003 (AFX-Europe via COMTEX) -- Schwarz Pharma AG said it will file in the third quarter of next year for worldwide marketing approval of its patch for the treatment of Parkinson's disease, rotigotine CDS, after Phase III studies demonstrated its safety and efficacy. Detailed results from the studies will be available in the first quarter of 2004, Schwarz said. The product, which has a peak sales potential of 350 mln eur, is one of Schwarz Pharma's six drug development projects. Fesoterodine for the treatment of overactive bladder/urinary incontinence is in Phase III trials, while three projects are in Phase II: harkoseride for the treatment of diabetic, neuropathic pain; the same drug for treatment of epilepsy; and rotigotine CDS for the treatment of Restless Legs Syndrome (RLS). Additionally, a project for benign prostate hyperplasia therapy is in Phase I trials. "For the next two years Schwarz Pharma projects to expand its development pipeline and to further strengthen its US business. Despite high investments Schwarz Pharma will still operate at a profit during these years. In the following years double-digit sales growth along with even higher growth in earnings is expected," the company said. In addition to its Research and Development pipeline, Schwarz Pharma has a total of eight specialty pharmaceutical projects in development for the US market. These projects are primarily drugs which use a well-established compound in a new formulation or medication form, and offer patients an additional benefit, Schwarz said. Of the eight projects for use in primary care, gastroenterology and neurology, five are already undergoing the FDA approval process, Schwarz said. Market introduction of the first product is planned for the middle of 2004. Given a successful market introduction, the expected sales potential of the total portfolio is 250-300 mln usd, it added. [log in to unmask] ds/cmr SOURCE: MacroWorld Investor http://www.mworld.com/m/m.w?lp=GetStory&id=76607681 * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn